Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy

What Was Tested

This randomized controlled trial paper looks at Amylin (Islet Amyloid Polypeptide).

Who Took Part

By PubMed's age tags, the people studied were adults, both men and women.

The researchers conducted a post hoc analysis of 2 studies: a 29-week, multicenter, randomized, double-blind, placebo-controlled trial (referred to as RCT) (pramlintide, n = 82; placebo, n = 73) and an open-ended, multicenter, open-label, single-arm, observational study (referred to as clinical practice trial) (n = 150), which assessed the addition of pramlintide to CSII therapy in patients with T1DM.

How the Study Was Run

In design terms this was a randomized, double-blind, open-label, placebo-controlled and multicenter study.

The participants were allocated by chance, so the Amylin (Islet Amyloid Polypeptide) group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Amylin (Islet Amyloid Polypeptide).

Nothing was hidden in this open-label Amylin (Islet Amyloid Polypeptide) study: the participants and staff both knew the treatment.

The comparison arm used a placebo, so changes seen with Amylin (Islet Amyloid Polypeptide) could be set against what happens without it.

What Was Measured

The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 1, Glycated Hemoglobin, Hypoglycemic Agents, Infusions, Subcutaneous, Insulin and Islet Amyloid Polypeptide.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Amylin (Islet Amyloid Polypeptide).

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2013 (Postgraduate medicine), a journal based in England.

More context: the Amylin (Islet Amyloid Polypeptide) compound page, all human trials.